pharmaceutical investing Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19
pharmaceutical investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
pharmaceutical investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
pharmaceutical investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
pharmaceutical investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
pharmaceutical investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
pharmaceutical investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
pharmaceutical investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
pharmaceutical investing Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19
Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Pan Global Expands Near-Surface High-Grade Gold Discovery at Cármenes Project, Spain: Drillholes Return 7.29g/t Au Over 9 Meters and 1.53g/t Au Over 38 Meters
Brixton Metals Samples New Vein Grading 195 g/t Gold, 4.11% Copper and 147 g/t Silver At Its Thorn Project
SAGA Metals Reports Final Titanium, Vanadium and Iron Assays from MRE Drilling-Maiden Mineral Resource Estimate Imminent
Silverco Mining Intercepts 1,280 g/t Silver over 3.35 Metres True Width at Its 100%-Owned Cusi Mine in Chihuahua, Mexico
